Clinical Trial Update: MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb [Phase 2]

View source ↗

Summary

This is a Phase 2 study of elranatamab (PF-06863135) as a monotherapy in adults with multiple myeloma who are refractory to a proteasome inhibitor, an IMiD, and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Elranatamab (elranatamab)

Snippet

Sponsor: Pfizer | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-10-25